Apollo Medical upgraded to Buy from Neutral at BofA

BofA upgraded Apollo Medical to Buy from Neutral with a price target of $55, up from $44. The firm sees an inflection point in the growth story, with “high confidence” in the path to sustaining 30%-40%-plus revenue and 20%-plus EBITDA growth through at least 2026. As a result, it is raising its estimates above the Street, the analyst tells investors.